Skip to content

Study of serum CA125 combined with NT-proBNP in patients with heart failure with obstructive sleep apnea syndrome

Study of serum CA125 combined with NT-proBNP in patients with heart failure with obstructive sleep apnea syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057471
Enrollment
Unknown
Registered
2022-03-13
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with obstructive sleep apnea syndrome

Interventions

Sponsors

Zhongda Hospital Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The diagnosis of heart failure conforms to the diagnostic criteria of heart failure in China Guidelines for the Diagnosis and Treatment of Heart Failure 2018; 2. OSAHS diagnosis is consistent with the diagnostic criteria of the 2011 Guidelines for the Diagnosis and Treatment of Obstructive Sleep Apnea; 3. Aged at least 18 years; 4. Have cognition and understanding ability, sign informed consent and pass the review of ethics committee.

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart valvular disease, pericardial disease, hypertrophic cardiomyopathy, restricted cardiomyopathy, acute heart failure, acute myocardial infarction; 2. Various acute and chronic infections (including a history of respiratory infection within the last 2 weeks), severe chronic obstructive and/or restrictive pulmonary diseases, cirrhosis of the liver, serum creatinine levels > 265umol/L, malignancies, and various severe cardiovascular and cerebrovascular diseases; Major trauma, surgery, blood disease, immune disease and other diseases that may cause changes in CA125 level within the last 1 month; 3. The pregnancy and patients with chronic use of sedatives, antipsychotics, hormones and alcoholism (> 80g/ day); 4. Mixed and central sleep apnea hypopnea syndromes were excluded in OSAS patients.

Design outcomes

Primary

MeasureTime frame
Carbohydrate antigen 125;NT-proBNP;IL-1ß;TNF-a;

Countries

China

Contacts

Public ContactGe Tiantian

Zhongda Hospital Southeast University

gttcardiology@163.com+86 18851720820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026